In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1855 News Items found
Alexander Rudensky
Harmful Immune Reactions Might One Day Be Curbed with Cell-Based Therapy

A team of researchers led by Memorial Sloan Kettering immunologist Alexander Rudensky has gained new understanding about regulatory T cells -- a subtype of immune cells that suppresses the immune system's reactivity.
Memorial Sloan Kettering Researchers Are 2010 Rock Stars of Science

Three Memorial Sloan Kettering Cancer Center investigators -- including the Center's new President, Craig B. Thompson -- have been featured with singer-songwriter Debbie Harry to lead the Geoffrey Beene Gives Back® 2010 Rock Stars of Science™ campaign in <i>GQ</i> magazine's December "Men of the Year" issue.
Hedvig Hricak (left) and David Scheinberg are members of the new Nanotechnology Center's executive committee, which Dr. Scheinberg chairs.
New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.
New Opportunities for Collaboration and Translation

As construction began on the Mortimer B. Zuckerman Research Center, SKI adopted new ways to advance therapeutic innovation at Memorial Sloan Kettering.
Zvi Fuks
Zvi Fuks Elected to the Institute of Medicine

Zvi Fuks has been elected a member of the Institute of Medicine, one of the highest honors in the fields of health and medicine.
Alexander Rudensky
An Interview With Alexander Rudensky

A member of the Sloan Kettering Institute's Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.
Samuel Danishefsky
Memorial Sloan Kettering Enters Agreement to Develop New Cancer Drug

As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
(From left) The first four authors of the June 24 Cancer Cell study, Barry Taylor, Anuradha Gopalan, Haley Hieronymous, and Nikolaus Schultz.
Sifting Through the Prostate Cancer Genome

A team of Memorial Sloan Kettering clinicians and computational biologists have compiled the largest catalog to date of genetic alterations that occur in prostate cancer.
Study Answers Important Question about Using Carbon Nanotubes in Medicine

A multicenter study led by Memorial Sloan Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.
Harold Varmus former CEO of MSK
Harold Varmus: A Decade of Leadership at MSK

Harold Varmus became President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center on January 1, 2000. He ended his decade-long tenure on July 1, 2010. And on July 12, 2010, Dr. Varmus took up a new role as Director of the National Cancer Institute.